Last updated on June 2019

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders


Brief description of study

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.

Clinical Study Identifier: NCT03601819

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.